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Summary. Background: A procoagulant state is implicated
in cerebral malaria (CM) pathogenesis, but whether dis-
seminated intravascular coagulation (DIC) is present or
associated with a fatal outcome is unclear. Objectives: To
determine the frequency of overt DIC, according to ISTH
criteria, in children with fatal and non-fatal CM.
Methods/patients: Malawian children were recruited into
a prospective cohort study in the following diagnostic
groups: retinopathy-positive CM (n = 140), retinopathy-
negative CM (n = 36), non-malarial coma (n = 14),
uncomplicated malaria (UM), (n = 91), mild non-malarial
febrile illness (n = 85), and healthy controls (n = 36).
Assays in the ISTH DIC criteria were performed, and
three fibrin-related markers, i.e. protein C, antithrombin,
and soluble thrombomodulin, were measured. Results and
conclusions: Data enabling assignment of the presence or
absence of ‘overt DIC’ were available for 98 of 140
children with retinopathy-positive CM. Overt DIC was
present in 19 (19%), and was associated with a fatal out-
come (odds ratio [OR] 3.068; 95% confidence interval
[CI] 1.085–8.609; P = 0.035]. The levels of the three fib-
rin-related markers and soluble thrombomodulin were
higher in CM patients than in UM patients (all
P < 0.001). The mean fibrin degradation product level
was higher in fatal CM patients (71.3 lg mL1
[95% CI 49.0–93.6]) than in non-fatal CM patients
(48.0 lg mL1 [95% CI 37.7–58.2]; P = 0.032), but, in
multivariate logistic regression, thrombomodulin was the
only coagulation-related marker that was independently
associated with a fatal outcome (OR 1.084 for each ng
mL1 increase [95% CI 1.017–1.156]; P = 0.014). Despite
these laboratory derangements, no child in the study had
clinically evident bleeding or thrombosis. An overt DIC
score and high thrombomodulin levels are associated with
a fatal outcome in CM, but infrequently indicate a con-
sumptive coagulopathy.
Keywords: blood coagulation; disseminated intravascular
coagulation; endothelial cell protein C receptor; fibrin;
malaria, cerebral.
Introduction
Cerebral malaria (CM) is a severe complication of Plas-
modium falciparum infection defined by unrousable coma,
P. falciparum parasitemia, and exclusion of other causes
of coma [1]. CM is most frequent in children in sub-
Saharan Africa, in whom it causes approximately 600 000
cases annually and 100 000 deaths [2]. The case fatality rate
is 10–20% [1], and there is currently no effective adjunctive
therapy [3]. A number of publications have indicated a
Correspondence: Christopher A. Moxon, Institute of Infection and
Global Health, University of Liverpool, 8 West Derby Street,
Liverpool L69 7BE, UK.
Tel.: +44 151 795 9667; fax: +44 151 795 9667.
E-mail: cmoxon@liverpool.ac.uk
The copyright line for this article was changed on 29 January 2016
after original online publication.
Received 9 February 2015
Manuscript handled by: M. Levi
Final decision: F. R. Rosendaal, 18 June 2015
© 2015 The Authors Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Thrombosis and Haemostasis, 13: 1653–1664 DOI: 10.1111/jth.13060
contribution to CM pathogenesis of coagulation disor-
ders [4–9]. In the light of new treatments aimed at the
coagulation–inflammation interface, including specific
thrombin [10] and factor Xa inhibitors [11] and recombi-
nant proteins [12,13], coagulopathy has been proposed as
a potential target for an adjunctive therapy to improve
outcome [14–18]. However, in non-immune adults with
CM, the relative rarity of clinically evident bleeding or
decompensation of coagulation factors has been inter-
preted as indicating that coagulopathy is important in
only a small proportion of individuals [19]. Large studies
that have included a variety of malaria syndromes seem
to indicate that bleeding is rare in children with CM
[20], but no study has provided specific data on the fre-
quency of bleeding or thrombosis in African children
with CM [21].
Several recent lines of evidence indicate that the activa-
tion of coagulation may play a role in CM pathogenesis.
In vitro, P. falciparum-infected erythrocytes (IEs) can
promote the development of a procoagulant endothelial
surface through induction of tissue factor [5] and by
directly binding to the active site of the anticoagulant
receptor endothelial protein C receptor (EPCR) [4]. In
postmortem samples from African children with CM, we
have shown that there is marked fibrin deposition, local-
ized to sites of IE sequestration and associated with
localized loss of the anticoagulant receptors EPCR and
thrombomodulin [16]. Significantly raised plasma throm-
bin–antithrombin complex (TAT) levels in patients with
CM imply that there is sufficient activation of coagula-
tion for this to be detected in the systemic circulation.
The fact that levels of circulating activated protein C-to-
prothrombin fragment ratio (F1+2) are similar in CM
and uncomplicated malaria (UM) suggests that coagula-
tion is generally compensated in CM patients [16]. These
data provide clear evidence of a localized coagulopathy
in the brain in CM, but it is unclear whether the activa-
tion of coagulation detected in plasma simply represents
the downstream detection of a purely cerebral event
or whether, in some individuals, IE-induced loss of
anticoagulant function may cause a systemic disturbance
of coagulation and lead to disseminated intravascular
coagulation (DIC).
To enable standardization between studies on the defi-
nition of DIC, the ISTH has devised a scoring system
based on the prothrombin time (PT), the platelet count,
and the circulating levels of fibrinogen and a soluble fib-
rin marker. We therefore measured these and other coag-
ulation indices in several groups of Malawian children:
those who met the case definition of CM; encephalopathic
aparasitemic patients; children with UM; children with
aparasitemic uncomplicated febrile illness; and healthy
controls (HCs). The objective of this study was to exam-
ine the association between the overt DIC score and its
components and mortality.
Materials and methods
Study population
Children aged 6 months to 12 years were recruited into
a prospective cohort study at Queen Elizabeth Central
Hospital, Blantyre, Malawi between January 2008 and
July 2011, and constitute the same cohort of patients
as in previously published data [16,22]. Some of the
data presented here (PT, platelet counts, TAT levels
and soluble thrombomodulin [sTM] levels from the
non-comatose patients only) were included in previously
published reports [16,22], but are presented here to
enable calculation of the DIC score and to compare
them with other factors analyzed for the first time. Six
patient groups were prospectively defined: retinopathy-
positive CM, retinopathy-negative CM, aparasitemic
coma, UM, mild aparasitemic febrile illness, and HCs.
In high-transmission areas such as Malawi, where a sig-
nificant proportion of apparently well children are para-
sitemic, the diagnosis of CM according to World
Health Organization (WHO) criteria [23] leads to mis-
classification in ~ 25% of cases [1]. In a parasitemic
comatose child, it is unclear whether the parasitemia
has caused the coma or whether another etiology –
infectious or non-infectious – has precipitated coma in
a child who already had asymptomatic parasitemia.
Classification of CM patients as retinopathy-positive or
retinopathy-negative, as assessed by an ophthalmologist
using dilated ophthalmoscopy [24], has emerged as an
important method for refining the diagnosis of CM.
The presence or absence of retinal whitening, vessel
changes and/or microhemorrhages is associated with
sequestration of IEs in cerebral vessels [25], and distin-
guishes definitive retinopathy-positive CM from
retinopathy-negative parasitemic encephalopathies, in
which another etiology is indicated as a cause of coma
[1]. Non-malarial coma was defined as a Blantyre coma
score of ≤ 2 in the absence of parasitemia and in the
absence of overt meningitis (i.e. cloudy cerebrospinal
fluid). The group includes children with both infectious
and non-infectious etiologies of coma, but the etiology
of coma is often not identified [26]. UM and mild
aparasitemic febrile illness patients had acute febrile ill-
ness without signs of organ compromise [20], and did
not require hospital admission. HCs were children
attending for elective surgery who were otherwise well,
who did not have a history of systemic illness, and
who were not receiving regular medication. Patients
were observed until discharge or death. The study was
approved by ethical boards at the College of Medicine
in Malawi (no. P.02/10/860) and the Liverpool School
of Tropical Medicine in the UK (no. 09.74). Informed
consent was obtained from the parents or guardians of
all of the children enrolled.
© 2015 The Authors Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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Global and molecular markers of coagulation activation
Blood was obtained by venepuncture at a single time
point on admission to hospital, and citrated plasma was
prepared as described previously [27]. Samples were fro-
zen immediately, and stored at  80 °C. Antithrombin
activity, protein C activity, the fibrinogen level (Claus
method) and the PT were determined on an MDA180
analyzer (Stago, D€usseldorf, France). Levels of fibrin
monomers, D-dimers, fibrin and fibrin degradation prod-
ucts (FDPs) were determined on an STA Compact CT
analyzer (Stago). F1+2, TAT and sTM levels were deter-
mined with commercial ELISA kits (Enzygnost TAT
micro [Dade Behring, Marburg, Germany]; sTM DY3947
[R&D, Minneapolis, MN, USA]). DIC was defined
according to ISTH criteria [28]. Normal values relevant
to the study population were defined as those in the
Malawian pediatric HCs.
Statistical methods
Statistical analysis was performed with STATA (version 11;
Statacorp, College Station, TX, USA) and PRISM (version
5.0; GraphPad, La Jolla, CA, USA) software. Continuous
variables were generally assumed to have a normal or a
log normal distribution, depending on their level of skew-
ness. Differences between groups for these variables were
compared by the use of either a t-test or ANOVA; for the
latter, the Tukey honestly significant difference test was
used to adjust for multiple comparisons. The relationship
between fatal outcome and baseline clinical and labora-
tory variables was assessed by the use of odds ratios
(ORs) and a logit model, with STATA software. The vari-
ables assessed were those that have previously been
shown to be associated with severe disease, i.e. admission
glucose level, hemoglobin level, histidine-rich protein-2
(HRP2) level, parasite count, and lactate level, and all of
the coagulation indices assessed in this study (PT, fibrino-
gen level, fibrin monomer level, FDP level, D-dimer level,
antithrombin activity, protein C activity, and thrombo-
modulin level). The OR indicates the estimated increase
in the log odds of a fatal outcome per unit increase (e.g.
thrombomodulin, each ng mL1; lactate, each mmol L1)
for each continuous variable. To adjust for age and sex,
these variables were included as independent variables in
the model. Missing data were handled by listwise deletion.
All tests were two-tailed with a conventional 5% a-level.
Results
The numbers of patients included in each of the groups
were as follows: retinopathy-positive CM, n = 140;
retinopathy-negative CM, n = 36; non-malarial coma,
n = 14; UM, n = 91; mild non-malarial febrile illness
(MF), n = 85; and HCs, n = 36. The case fatality rate did
not differ significantly between children with retinopathy- T
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positive CM (16.4%) and those with retinopathy-negative
CM (13.9%) or non-malarial coma (13%) (P = 0.8; the
case definitions and significance of these three encephalo-
pathic groups are detailed under ‘Study population’ in
Materials and methods). Outcome data were complete for
all hospitalized patients. Other parameters are compared
in Table 1.
Evidence of fibrin generation
The plasma levels of several different markers of fibrin
breakdown – D-dimers, FDPs, and soluble fibrin mono-
mers (Fig. 1) – all indicated greater fibrin generation and
breakdown in retinopathy-positive CM patients than in
the non-comatose comparator groups (HC, MF, and
UM; all P < 0.001). There was evidence of moderately
increased fibrin production in children with non-malarial
coma and retinopathy-negative CM. Significant differ-
ences (Fig. 1A,B) between children with retinopathy-posi-
tive CM and these other comatose clinical groups
indicated that fibrin generation was particularly increased
in retinopathy-positive CM patients. Among retinopathy-
positive patients, the geometric mean FDP level was signifi-
cantly higher in children who went on to die (71.3 lg mL1;
95% confidence interval [CI] 49.0–93.6) than in those who
survived (48.0 lg mL1; 95% CI 37.7–58.2; P = 0.032),
but the mean D-dimer and fibrin monomer levels, although
higher in survivors, were not significantly so (P = 0.25
and P = 0.44, respectively). Taken together, these data
indicate that fibrin production is associated with the diag-
nosis of retinopathy-positive CM, and that patients with
high levels of fibrin generation are more likely to die.
Frequency of overt DIC in CM and its association with a
fatal outcome
The ISTH scoring system for overt DIC makes use of the
PT, the platelet count, and fibrinogen levels, in addition to
a soluble fibrin marker, to calculate a combined coagula-
tion score [29]. The mean PT was significantly prolonged
in both retinopathy-positive CM and retinopathy-negative
CM patients as compared with HCs (Fig. 2A; both
P < 0.01), but was not significantly different between
retinopathy-positive CM and retinopathy-negative CM
patients, or between retinopathy-positive CM patients
and the other clinical groups (Fig. 2A). Specifically for
children with retinopathy-positive CM, the PT was simi-
lar between children with a fatal outcome (geometric
mean, 18.3 s; 95% CI 15.9–22.4 s) and children who sur-
vived (16.6 s; 95% CI 15.9–17.4 s; P = 0.06). Consistent
with previously published data [30], the platelet count
was markedly reduced in UM, retinopathy-positive CM
and retinopathy-negative CM patients, and was lower
in retinopathy-positive CM patients than in all of the
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Fig. 1. Increased plasma markers of intravascular fibrin generation in cerebral malaria (CM). (A) Plasma D-dimer levels measured on admis-
sion/presentation in children with retinopathy-positive CM (n = 102), retinopathy-negative CM (n = 31), non-malarial coma (n = 11), uncom-
plicated malaria (UM) (n = 55), and mild non-malarial febrile illness (MF), (n = 28), and in healthy controls (HCs) (n = 27). (B) Plasma fibrin
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intervals. Significance was determined by ANOVA with the Tukey honestly significant difference test on log-transformed data to adjust for multi-
ple comparisons. ***P < 0.001. NS, not significant.
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Fig. 2. ISTH score for overt disseminated intravascular coagulation (DIC) and its components in cerebral malaria (CM) patients and comatose
and non-comatose controls. (A, B) Prothrombin time (PT) (A) and fibrinogen (B) in children with retinopathy-positive CM (n = 70), retinopa-
thy-negative CM (n = 23), non-malarial coma (n = 11), uncomplicated malaria (UM) (n = 21), and mild non-malarial febrile illness (MF)
(n = 24), and in healthy controls (HCs) (n = 30). The red dashed lines in (A) and (B) indicate a PT prolonged by 3 s over the geometric mean
of the HCs (≥ 17.4 s) and a fibrinogen level of > 1 g L1, the threshold for these indices in the overt DIC score. (C) Platelet count (9106 L1)
in children with retinopathy-positive CM (n = 138), retinopathy-negative CM (n = 39), non-malarial coma (n = 19), UM (n = 88), and MF
(n = 77), and in HCs (n = 28). The red dashed line indicates a platelet count of 100 000 9 106 L1. (D) ISTH DIC scores in children with
retinopathy-positive CM (n = 55), retinopathy-negative CM (n = 16), and non-malarial coma (n = 12). For 43 retinopathy-positive CM
patients, 10 retinopathy-negative CM patients, and two non-malarial coma patients, data were missing for one or two components, and so a
score is not shown, but either the score was already ≥ 5 or it would not reach ≥ 5 regardless of the missing data, and so the presence or
absence of overt DIC could still be assigned with certainty. The red dashed line indicates a score of ≥ 5, the threshold for overt DIC. Horizon-
tal lines indicate geometric means, and bars indicate 95% confidence intervals. Significance was determined by ANOVA with the Tukey honestly
significant difference test on log-transformed data to adjust for multiple comparisons. **P < 0.01, ***P < 0.001. The data in (A) and (C) have
been published previously [16], but are presented again here for comparison with other coagulation parameters and to enable calculation of the
ISTH DIC score. NS, not significant.
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other clinical groups (Fig. 2C; all P < 0.001). However,
as previously shown [30], in retinopathy-positive CM
patients, the platelet count was not significantly associ-
ated with a fatal outcome (fatal, 60 262 platelets dL1,
95% CI 42 820–77 705; non-fatal, 67 069 platelets dL1,
95% CI 60 275–73 864; P = 0.43). The geometric mean
fibrinogen levels in retinopathy-positive CM patients were
significantly higher than those in HCs, although there
was a wide spread of data (Fig. 2B). All except three
retinopathy-positive CM patients had fibrinogen levels of
> 1 g L1, the defined lower cut-off taken to indicate
consumptive coagulopathy in the ISTH scoring system,
and no patients reached this cut-off in any of the com-
parator groups. In the subgroup of retinopathy-positive
children, there was no association between fibrinogen
levels and fatal outcome (fatal, mean of 3.6 g L1,
95% CI 2.2–5.0 g L1; non-fatal, mean of 4.4 g L1,
95% CI 4.0–4.8 g L1; P = 0.18). We used fibrin mono-
mers rather than D-dimer or FDPs in the calculation of
the DIC score, as there is evidence that it is a more speci-
fic marker of coagulation activation and fibrin generation
[31,32]; however, the fibrin marker used had only a minor
effect on the assignment of DIC score (data not shown).
A complete set of parameters were available for 55
retinopathy-positive CM patients, 16 retinopathy-negative
CM patients, and 12 non-malarial coma patients
(Fig. 2D). In additional patients, although one or two
parameters were missing, either the score was already ≥ 5
or would not reach ≥ 5 irrespective of the value of the
missing parameters, and so the presence or absence of
overt DIC could still be assigned with certainty. A score
indicative of overt DIC (≥ 5) was present in 19 of
98 (19%) retinopathy-positive CM patients, two of 26
(8%) retinopathy-negative CM patients, and two of 14
(14%) non-malarial coma patients. In the subgroup of
retinopathy-positive CM patients, 10 (32%) of the 31
patients with an overt DIC score died (OR 3.068;
95% CI 1.085–8.609; P = 0.035), as compared with nine
(13.4%) of the 67 patients who did not have overt DIC,
and eight (19%) of the 42 patients for whom we did not
have all of the data needed to calculate a DIC score.
Among retinopathy-negative CM patients, only two
patients had overt DIC, both of whom survived. Five
(21%) of 17 patients who did not have overt DIC died,
as compared with two (10%) of the 20 patients for
whom we did not have all of the data needed to calculate a
DIC score.
Several case reports have described an association
between quinine therapy and DIC [33]. Given that the
majority of our patients had received quinine therapy
prior to blood sampling, either in a peripheral health cen-
ter or immediately on arrival at hospital, we examined
whether overt DIC was associated with prior quinine
therapy. Data on prior quinine therapy were available for
63 patients: 16 who had overt DIC, and 49 who did not.
Eleven of the 16 patients (69%) who had overt DIC
received quinine prior to blood being taken, as compared
with 43 of the 47 patients (91%) who did not have overt
DIC. Prior quinine treatment was therefore associated
with protection from rather than an increased risk of
overt DIC (OR 0.205; 95% CI 0.035–1.160; P = 0.039).
These data indicate that there is an association between
a prothrombotic state and the diagnosis of retinopathy-
positive CM, and that, within this group, a prothrom-
botic state is associated with an adverse outcome.
Clinically apparent bleeding or thrombosis was not noted
in any patient in this study, including the 19 CM patients
with a positive overt DIC score. To ensure that we had
not, through bias in recruitment of blood samples, missed
significant coagulopathies associated with CM in the pop-
ulation of Malawian children presenting to our unit, we
conducted a notes review of all 104 patients admitted
with CM in 2008, and did not identify clinically evident
bleeding or thrombosis in any of them.
Anticoagulant factors in CM
Both antithrombin activity (Fig. 3A) and protein C activ-
ity (Fig. 3B) were decreased in retinopathy-positive CM
patients as compared with non-comatose controls (HC,
MF, and UM; all P < 0.001) and non-malarial coma
patients (P < 0.001). In CM patients, protein C activity
was lower than antithrombin activity, but the percentage
differences between HCs and retinopathy-positive CM or
retinopathy-negative CM patients were similar for both
molecular markers (Fig. 3A,B). In the subgroup of
retinopathy-positive CM children, antithrombin activity
and protein C activity were not significantly different in
fatal and non-fatal cases (Fig. 3C,D).
sTM levels in CM
Plasma levels of sTM constitute an established marker of
endothelial damage in DIC [34], and we have shown that
thrombomodulin is lost at sites of IE sequestration and
fibrin deposition in CM [16]. The geometric mean plasma
sTM level was significantly higher in retinopathy-positive
CM patients than in all of the other clinical groups
(Fig. 4A). Among retinopathy-positive CM patients, geo-
metric mean sTM levels were higher in patients who died
(14.5 ng mL1; 95% CI 9.5–22.1) than in those who sur-
vived (8.2 ng mL1; 95% CI 6.6–10.1; P < 0.001;
Fig. 4B).
Risk factors associated with a fatal outcome in CM patients
A logistic regression model was generated, adjusting for
age and sex, with outcome (fatal or non-fatal) as the
dependent variable, and factors associated with severe
malaria and coagulation indices as independent variables
(plasma lactate, hemoglobin, blood glucose, parasite
count, and HRP2). The results of univariate analysis are
© 2015 The Authors Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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Fig. 3. Decreased anticoagulant activity in cerebral malaria (CM) and association with outcome. (A) Antithrombin activity measured at admis-
sion in children with retinopathy-positive CM (n = 68), retinopathy-negative CM (n = 19), non-malarial coma (n = 11), uncomplicated malaria
(UM) (n = 19), and mild non-malarial febrile illness (MF) (n = 13), and in healthy controls (HCs) (n = 29). (B) Protein C activity in children
with retinopathy-positive CM (n = 68), retinopathy-negative CM (n = 21), non-malarial coma (n = 11), UM (n = 20), and MF (n = 18), and in
HCs (n = 30). (C) Antithrombin activity at admission in patients with retinopathy-positive CM grouped according to outcome: those who even-
tually died (fatal, n = 12) and those who survived (non-fatal, n = 54). (D) Protein C activity in fatal (n = 12) and non-fatal cases (n = 56) of
retinopathy-positive CM. Horizontal lines indicate means, and bars indicate 95% confidence intervals. In (A) and (B), significance was deter-
mined by ANOVA with the Tukey honestly significant difference test to adjust for multiple comparisons. In (C) and (D), significance was deter-
mined with a two-tailed t-test. *P < 0.05, ***P < 0.001. ATIII, antithrombin; NS, not significant.
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shown in Table 2. Lactate, glucose, thrombomodulin,
TATs, FDPs and overt DIC were significantly associated
with mortality on univariate regression. When a multi-
variate logistic regression model was employed, only sTM
(OR 1.084; 95% CI 1.017–1.156; P = 0.014), blood glu-
cose (OR 1.218; 95% CI 1.051–1.412; P = 0.009 and
plasma lactate (OR 1.204; 95% CI 1.049–1.382;
P = 0.008) were independent predictors of mortality
(Table 3). As a fibrin marker (fibrin monomers) is already
used to determine overt DIC, to avoid collinearity, only
FDPs or overt DIC were used in any given model.
Nonetheless, although both were significantly associated
with mortality on univariate analysis, neither overt DIC
nor FDP levels were independently predictive of fatal out-
come when glucose, thrombomodulin, lactate, age and
sex were included in the model.
Effect of HIV on DIC score and coagulation indices
Eleven children in the retinopathy-positive group were
HIV-positive. WHO clinical staging data [35] were avail-
able for six patients, all of whom were clinical stage 1.
We compared the different coagulation parameters in the
HIV-positive and HIV-negative children, and found no
evidence of an effect of HIV on any parameter or on the
DIC score (Table S1).
No association between plasma coagulation makers and
retinal hemorrhages in CM
Although the vasculature of the brain is inaccessible dur-
ing life, examination of the retinal neurovasculature by
funduscopy provides ‘a window into the brain’, with a
high correlation between premortem retinal changes
in vivo and postmortem vasculature changes in the brain
[36]. To assess whether intravascular coagulation in the
neurovasculature is associated with a procoagulant state,
we assessed the association of fibrin markers, activation
of coagulation and DIC score with retinal hemorrhages.
Among retinopathy-positive CM patients, we had data on
both DIC score and retinal examination for 59 patients.
A positive score for overt DIC was not associated with
the presence of retinal hemorrhages (OR 0.59;
95% CI 0.21–1.69; P = 0.33). On univariate analysis,
none of the fibrin markers (fibrin monomers, FDPs, or
D-dimers), coagulation measurements (PT, TAT,
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Fig. 4. Increased plasma soluble thrombomodulin (sTM) levels in children with cerebral malaria (CM) and association with fatal outcome. (A)
Plasma sTM levels measured at admission in children with retinopathy-positive CM (n = 115), retinopathy-negative CM (n = 23), non-malarial
coma (n = 10), uncomplicated malaria (UM) (n = 103), and mild non-malarial febrile illness (MF) (n = 95), and in healthy controls (HCs)
(n = 36). (B) Admission sTM levels in fatal (n = 24) and non-fatal (n = 91) cases. Horizontal lines indicate means, and bars indicate 95% confi-
dence intervals. Significance in (A) was determined by ANOVA with the Tukey honestly significant difference test to adjust for multiple compar-
isons. Significance in (B) was determined with a two tailed t-test. *P < 0.05, ***P < 0.001. The data from the HCs and from the MF and UM
patients have been published previously [22], but are presented again here for comparison with new data from non-malarial comatose, retinopa-
thy-negative CM and retinopathy-positive CM patients, and in the context of outcome.
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antithrombin III, protein C, and fibrinogen), platelet
count or DIC score was significantly associated with reti-
nal hemorrhages (P > 0.1).
Discussion
We have systematically investigated the presence of DIC
in African children with CM by using validated interna-
tional criteria. Approximately one-fifth of children for
whom we had data to calculate the DIC score met the
ISTH criteria for overt DIC, despite none of these
patients having clinically evident bleeding or fulminant
thrombosis.
Previously, in brain tissue from children with fatal CM,
we demonstrated intravascular fibrin deposition specific
to retinopathy-positive CM, occurring at sites of seques-
tration of IEs in association with loss of endothelial pro-
tein C and thrombomodulin [16]. The increased levels of
fibrin markers shown in the current study demonstrate
that fibrin formation occurs in vivo, and provide evidence
for the thrombosis observed postmortem being not merely
a perimorbid event, but being representative of a process
that is occurring when children with CM present to hos-
pital. Retinopathy-positive CM patients had higher levels
of fibrin markers and were more likely to have overt DIC
than retinopathy-negative CM or aparasitemic comatose
patients – both groups of sick patients in coma with simi-
lar case fatality rates. Furthermore, retinopathy-positive
CM patients who had laboratory-defined overt DIC at
presentation were three times more likely to die than
those who did not. Together with previous studies
[5,16,37], these findings strongly indicate the the involve-
ment of a procoagulant state and intravascular coagula-
tion in CM pathogenesis.
However, despite a positive overt DIC score in 19 of
98 retinopathy-positive CM patients and significantly
increased fibrin generation, none of these patients had
clinically apparent bleeding or major thrombotic episodes.
Although bleeding is recognized in African children with
CM, these and previous data [20] indicate that it is
uncommon. Although there are case reports of fulminant
thrombosis, such as purpura or limb ischemia, in non-im-
mune adults with severe malaria [38], we have not identified
any such reports in children with malaria. If fulminant
thrombosis does occur in African children with CM, it is
very rare. This is in contrast to other systemic infections
that activate coagulation, such as bacterial sepsis, in which
bleeding and fulminant thrombosis are more common (seri-
ous bleeding in 7% in a recent pediatric sepsis trial [39] and
purpura in 30%; limb ischemia resulting from thrombosis is
less common but well described). It is also noteworthy that
only three patients had low circulating fibrinogen levels,
Table 3 Multivariate logistic regression analysis of mortality out-
come with age, sex and thrombomodulin, glucose and lactate levels
as covariates
N OR 95% CI P
Age 114 0.986 0.951–1.008 0.160
Sex 114 1.170 0.746–17.056 0.111
Thrombomodulin 114 1.084 1.017–1.156 0.014
Plasma lactate 114 1.204 1.049–1.382 0.008
Blood glucose 114 1.218 1.051–1.412 0.009
CI, confidence interval; OR, odds ratio. The OR indicates the esti-
mated increase in the log odds of a fatal outcome per unit increase
(e.g. thrombomodulin, each ng mL1; lactate, each mmol L1) for
each continuous variable.
Table 2 Univariate analysis of association of covariates with a fatal outcome
Covariate N OR 95% CI P
Age (months) 139 0.983 0.964–1.002 0.083
Sex (male/female) 139 0.862 0.365–2.029 0.733
Prothrombin time (s) 67 1.126 0.970–1.306 0.118
Fibrin monomers (lg mL1) 114 1.003 0.996–1.010 0.422
Fibrin degradation products (lg mL1) 74 1.013 1.001–1.025 0.035
D-dimers (lg mL1) 102 1.039 0.967–1.117 0.292
Fibrinogen (g L1) 67 0.997 0.993–1.001 0.167
Thrombin–antithrombin complexes (lg L1) 74 1.016 1.003–1.027 0.010
Antithrombin activity (%) 66 0.969 0.927–1.014 0.149
Protein C activity (%) 65 1.000 0.967–1.036 0.967
Platelets (9 106 L1) 129 1.000 1.000–1.000 0.925
Overt DIC (yes/no) 98 3.068 1.085–8.609 0.035
DIC score 55 1.384 1.041–1.841 0.025
Thrombomodulin (ng mL1) 115 1.091 1.029–1.158 0.004
Lactate (mmol L1) 140 1.174 1.061–1.300 0.002
Histidine-rich protein-2 (ng mL1) 51 1.001 0.999–1.003 0.496
Parasitemia (parasites lL1) 136 1.000 1.000–1.000 0.835
Hemoglobin (g dL1) 137 0.947 0.761–1.178 0.625
Blood glucose (mmol L1) 140 1.138 1.000–1.295 0.049
CI, confidence interval; DIC, disseminated intravascular coagulation; OR, odds ratio. The OR indicates the estimated increase in the log odds
of a fatal outcome per unit increase (e.g. thrombomodulin, each ng mL1; lactate, each mmol L1) for each continuous variable.
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indicating that fibrinogen consumption rarely outstrips
production, and hence that, systemically, coagulation
remains compensated. We suggest that, in Malawian chil-
dren with CM, these observations are in keeping with
intravascular coagulation that is restricted to the microvas-
culature, at sites of IE sequestration, and particularly in the
vulnerable vascular bed of the brain. The markedly raised
sTM levels, which are specific to retinopathy-positive CM,
and the association between thrombomodulin levels and
fatal outcome – more strongly than, and independently of,
other coagulation factors – further support the role of the
protein C pathway in the etiology of this intravascular
coagulation in CM [4,16,40]. Thrombomodulin, which is a
key receptor in the protein C pathway, is predominantly
expressed in the microvasculature, and we have previously
shown its loss – putatively by receptor shedding – in associ-
ation with fibrin deposition at sites of sequestration [16].
Whether or not this coagulopathy is as localized in adults
with CM remains to be determined.
The lack of an association between retinal hemorrhages
and coagulation indices may be another indicator that
elevated coagulation indices constitute a downstream and
insensitive indicator of intravascular coagulation in the
neurovasculature. Another potentially overlapping expla-
nation for a lack of association between hemorrhages and
coagulation indices is that hemorrhages constitute an
insensitive indicator of thrombosis. In support of this,
previously in postmortem brain samples, we detected fib-
rin in 64% of vessels in fatal CM cases, whereas we
detected hemorrhage in only 2.4% of vessels [16].
Whereas fibrin deposition occurred in all individuals
examined, hemorrhages were present in only ~ 75%
[1,16,41]. In both retinal and cerebral tissue, it remains to
be determined why hemorrhages develop in certain vessels
and in some, but not all, children with CM.
The strengths of our study include the strict criteria
applied in the diagnosis of CM, which was further refined
by the use of retinal examination. In addition, we had
well-stratified comparator groups within the local popula-
tion, with both comatose and non-comatose cohorts, and
we established normal values from healthy Malawi chil-
dren. Even with a large, carefully controlled study of this
kind, there will be limitations. First, undertaking the study
in a pediatric population limited the volume of blood that
could be collected, and this meant that we were not able
to measure all factors in all patients. This limited the num-
bers of cases for analysis for some factors. Blood was
taken at only one time point, representing a snapshot in
the disease process, with the possibility that different
patients are captured at different points in the course of
illness. This may be particularly important when an asso-
ciation with mortality is examined, as we may have failed
to detect an association in patients presenting early as
opposed to those presenting late in their illness.
The significant intravascular fibrin production and
raised thrombomodulin levels demonstrated in this study,
specific to children with retinopathy-positive CM, add to
our previous data indicating a role of microvascular
thrombosis, in association with disruption of the pro-
tein C pathway, in the pathogenesis of the disease. The
findings provide further evidence to suggest that the pro-
tein C receptor loss and fibrin deposition in the cerebral
microvasculature observed postmortem is already occur-
ring at the time when children present to hospital. We
show significant laboratory evidence that derangement of
coagulation occurs in CM, and that the derangement is
greatest in those patients who go on to die. In contrast to
other conditions that cause a procoagulant state and lead
to positive overt DIC scores, this derangement rarely
leads to bleeding, fulminant thrombosis, or consumptive
coagulopathy. The use as adjunctive therapy in CM of
agents that prevent thrombin or fibrin generation war-
rants further investigation.
Addendum
C. A. Moxon, R. S. Heyderman, and C-H. Toh had the
idea for this study. T. E. Taylor, M. E. Molyneux, and
K. B. Seydel coordinated the overarching malaria patho-
genesis study. N. V. Chisala, C. Downey, and C. A. Moxon
performed the coagulation assays. I. MacCormick and
S. Harding collated the fundoscopy data. C. A. Moxon
analyzed the data and prepared the first draft of the
manuscript, with input from other authors. All authors
approved the final manuscript.
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